Clinical Trials Logo

Metastatic Breast Cancer clinical trials

View clinical trials related to Metastatic Breast Cancer.

Filter by:

NCT ID: NCT04163159 Recruiting - Clinical trials for Metastatic Breast Cancer

Genetic Markers of Circulating Tumor DNA for Monitoring Breast Cancer Patients in Costa Rica

Start date: January 7, 2019
Phase:
Study type: Observational

The use of circulating tumor DNA (ctDNA) as a noninvasive test for breast cancer monitoring throughout the course of the disease

NCT ID: NCT04159818 Recruiting - Clinical trials for Metastatic Breast Cancer

Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients

TONIC-2
Start date: February 21, 2020
Phase: Phase 2
Study type: Interventional

This is a single center non-blinded randomized multi-cohort non-comparative phase II trial with a Simon's two-stage design.

NCT ID: NCT04143906 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer

Start date: October 25, 2019
Phase: Phase 2
Study type: Interventional

Development of an active second-line treatment option for metastatic breast cancer patients previously pre-treated with anthracyclines and taxanes in neoadjuvant, adjuvant or palliative settings. For each randomisation arm, 100 patients will be included. The trial was performed as a 2-stage phase II study according to the optimal design by Simon with overall response rate as the primary objective. Study Design: Arm A: Vinorelbine 25 mg/m2 d1,8; Carboplatin AUC=6 d1 q 3 weeks; Arm B: Gemcitabine 1000 mg/m2 d1,8; Carboplatin AUC=6 d1 q 3 weeks;

NCT ID: NCT04143282 Completed - Clinical trials for Metastatic Breast Cancer

Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment

Start date: October 20, 2019
Phase: Phase 2
Study type: Interventional

This study aims to determine the effect of metformin along with standard cancer treatment, and its effect on the prognosis of the metastatic breast in non-diabetic patients.

NCT ID: NCT04140526 Recruiting - Ovarian Cancer Clinical Trials

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

PRESERVE-001
Start date: September 16, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

NCT ID: NCT04134884 Completed - Clinical trials for Metastatic Breast Cancer

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Start date: April 1, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase I study to test the safety of a combination of ASTX727 with talazoparib in patients with triple negative breast cancer or hormone resistant/HER2-negative metastatic breast cancer

NCT ID: NCT04129346 Completed - Obesity Clinical Trials

Technology-Supported Physical Activity Intervention for Metastatic Breast Cancer Survivors: Fit2ThriveMB

Start date: November 26, 2019
Phase: N/A
Study type: Interventional

This study will test the feasibility and acceptability of increasing PA in metastatic breast cancer (MBC) patients using a smartphone app, fitbit and coaching.

NCT ID: NCT04120298 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

Effects of Exercise in Patients With Metastatic Breast Cancer

EFFECT
Start date: January 8, 2020
Phase: N/A
Study type: Interventional

Currently, the effect of exercise on metastatic breast cancer has not been extensively studied, even though the benefits are evident in the curative setting. The investigators designed the EFFECT study to assess the effects of a 9-month structured and individualised exercise intervention in 350 patients with metastatic breast cancer (stage IV) on cancer-related physical fatigue, Health-Related Quality of Life (HRQoL), and other disease and treatment-related side effects at six months (primary endpoint).

NCT ID: NCT04115306 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

Dauntless-1
Start date: November 14, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.

NCT ID: NCT04103853 Completed - Clinical trials for Metastatic Breast Cancer

Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer

Start date: September 6, 2017
Phase: Phase 1
Study type: Interventional

This study is a multi-center, open-label, dose-esclation I/Ib clinical study to explore safety, efficacy an pharmacokinetics of proxalutamide in patients with metastatic breast cancer. This study includes two stages, stage I: single- and multiple-dose tolerance and pharmacokinetic study; stage 2: preliminary efficacy and safety study.